SmartLabs CEO, Amrit Chaudhuri, was interviewed by Fierce Biotech during 2023 JPM Week. Tune in to hear Amrit discuss the biggest challenges in the biotech industry, and how SmartLabs is tackling them. 

SmartLabs CEO, Amrit Chaudhuri, was recently interviewed by Executive Platforms during the 2022 Biomanufacturing World Summit. Listen in as Amrit discusses issues and trends in the biopharma industry and where SmartLabs plays an integral role in providing a solution for therapeutic companies!

The Cell, Gene, & Immunotherapy event is for manufacturing efficiencies, cost, and quality. 

Accelerate your bioprocessing, analytics, supply chain security and commercialization strategies by accessing novel science, technologies and the contacts you need

For more than 10 years, The Bioprocessing Summit has been recognized as the premier forum for industry leaders to share the latest research in bioprocess R&D, scale-up, quality and analytics.

Recently, Biopharma and Life Science companies are facing dramatic devaluations which have made a negative impact on private funding and have left growing companies navigating a series of complex decisions as their business grows. 

Listen in as SmartLabs Co-Founder/CBO, Seth Taylor, moderates a discussion with Todd Foley, Managing Director of MPM Capital, and Chad Cowen, CEO of Clade Therapeutics, on the current market and its implications for growing companies. 

The American Association for Laboratory Animal Science (AALAS) is a membership association of professionals employed around the world in academia, government, and private industry who are dedicated to the humane care and treatment of laboratory animals, as well as the quality research that leads to scientific gains

The Cell & Gene Meeting on the Mesa is the sector's foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.

Editas Medicine, Inc. EDIT is making good progress with the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing, to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness.

New York City has set up a new advisory panel of developers, brokers and investors to advise how the city's real estate can be leveraged to better serve and grow its nascent life sciences industry.

TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Eric Sullivan as Chief Financial Officer where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations.

 Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that new research highlighting the company’s internal efforts to develop improved transplant conditioning regimens for patients with sickle cell disease (SCD) undergoing hematopoietic stem cell transplantation (HSCT) will be presented today, June 27, 2022, at

Revolutionizing cell and gene engineering - ground breaking autologous and allogeneic treatments for blood borne and solid tumors